Document:

EX-10.3

   

           Exhibit 10.3

       CYTOMX THERAPEUTICS, INC.    	

  2015 EQUITY INCENTIVE PLAN 

  RESTRICTED SHARE UNIT AWARD GRANT NOTICE

  CytomX Therapeutics, Inc., a Delaware corporation, (the “Company”), pursuant to its 2015 Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an award of restricted share units (“Restricted Share Units” or “RSUs”).  Each vested Restricted Share Unit represents the right to receive, in accordance with the Restricted Share Unit Award Agreement attached hereto as Exhibit A (the “Agreement”), one Share.  This award of Restricted Share Units is subject to all of the terms and conditions set forth herein and in the Agreement and the Plan, each of which are incorporated herein by reference.  Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Restricted Share Unit Award Grant Notice and the Agreement.

  		
	Participant:
	[__________________________]

	Grant Date:
	[__________________________]

	Total Number of RSUs:
	[_____________] 

	Vesting Commencement Date:
	[_____________]

	Vesting Schedule:
	Except as otherwise provided in the Plan, the RSUs shall vest [_____________], if, and only if, Participant is, and has been, continuously (except for any absence for vacation, leave, etc. in accordance with the Company’s or its Subsidiaries’ policies): (i) employed by the Company or any of its Subsidiaries, (ii) serving as a Non-Employee Director or (iii) providing services to the Company or any of its Subsidiaries as an advisor or consultant, in each case, from the Grant Date through and including such date.   

	Termination:
	In the event Participant ceases to continuously be (except for any absence for vacation, leave, etc. in accordance with the Company’s or its Subsidiaries’ policies): (i) employed by the Company or any of its Subsidiaries, (ii) serving as a Non-Employee Director or (iii) providing services to the Company or any of its Subsidiaries as an advisor or consultant, then all RSUs that have not become vested on or prior to the date of such termination will thereupon be automatically forfeited by Participant without payment of any consideration therefor.  

  Participant understands that the terms of this award of RSUs explicitly include the following (a “Sell to Cover”):

  Upon vesting of the RSUs and issuance of the resulting Shares, the Company, on Participant’s behalf, will instruct the Company’s transfer agent (together with any other party the Company determines necessary to execute the Sell to Cover, the “Agent”) to sell that number of Shares determined in accordance with Section 2.6 of the Agreement as may be necessary to satisfy any resulting withholding tax obligations on the Company, and the Agent will remit the cash proceeds of such sale to the Company. The Company shall then make a cash payment equal to the required tax withholding from the cash proceeds of such sale directly to the appropriate taxing authorities.

  If the Company uses an electronic capitalization table system (such as Shareworks, Carta or Equity Edge) and the fields in this Grant Notice are blank or the information is otherwise provided in a different format 

  	 

  |US-DOCS\127381020.1||	|  DATE \@ "MM-dd-yyyy" 12-30-2021|

  

   

  electronically, the blank fields and other information will be deemed to come from the electronic capitalization system and is considered part of this Grant Notice.

  By his or her signature and the Company’s signature below, Participant agrees to be bound by the terms and conditions of the Plan, the Agreement and this Grant Notice.  Participant has reviewed the Plan, the Agreement and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, the Agreement and this Grant Notice. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan, the Agreement or this Grant Notice.  

  				
	CYTOMX THERAPEUTICS, INC.: Participant:
	PARTICIPANT:

	By:
	 
	By:
	 

	Print Name: 
	 
	Print Name:  
	 

	Title:
	 
	   
	 

	Address: 
	 
	Address: 
	 

	 
	 
	 
	 

   

  	 

  |US-DOCS\127381020.1||	|  DATE \@ "MM-dd-yyyy" 12-30-2021|

  

   

  EXHIBIT A

  TO RESTRICTED SHARE UNIT AWARD GRANT NOTICE

  RESTRICTED SHARE UNIT AWARD AGREEMENT

  Pursuant to the Restricted Share Unit Award Grant Notice (the “Grant Notice”) to which this Restricted Share Unit Award Agreement (this “Agreement”) is attached, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), has granted to Participant the number of restricted share units (“Restricted Share Units” or “RSUs”) set forth in the Grant Notice under the Company’s 2015 Equity Incentive Plan, as may be amended from time to time (the “Plan”).  Each Restricted Share Unit represents the right to receive one Share upon vesting.

  ARTICLE I.
GENERAL

  I.1Defined Terms.  Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Grant Notice.

  I.2Incorporation of Terms of Plan.  The RSUs are subject to the terms and conditions of the Plan, which are incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.

  ARTICLE II.
GRANT OF RESTRICTED SHARE UNITS

  II.1Grant of RSUs.  Pursuant to the Grant Notice and upon the terms and conditions set forth in the Plan and this Agreement, effective as of the Grant Date set forth in the Grant Notice, the Company hereby grants to Participant an award of RSUs under the Plan in consideration of Participant’s past and/or continued employment with or service to the Company or any Subsidiary and for other good and valuable consideration, subject to adjustments as provided in Sections 5.7 and 5.8 of the Plan. 

  II.2Unsecured Obligation to RSUs.  Unless and until the RSUs have vested in the manner set forth in Article II hereof, Participant will have no right to receive a Share or other property under any such RSUs.  Prior to actual payment of any vested RSUs, such RSUs will represent an unsecured obligation of the Company, payable (if at all) only from the general assets of the Company.  

  II.3Vesting Schedule.  Subject to Section 2.5 hereof, the RSUs shall vest and become nonforfeitable with respect to the applicable portion thereof according to the vesting schedule set forth in the Grant Notice (rounding down to the nearest whole Share).  Notwithstanding the foregoing and the Grant Notice, but subject to Section 2.5 hereof, in the event of a Change in Control, the RSUs shall be treated pursuant to Section 5.8 of the Plan.

  II.4Consideration to the Company.  In consideration of the grant of the award of RSUs pursuant hereto, Participant agrees to render faithful and efficient services to the Company and its Subsidiaries, as applicable.  

  II.5Forfeiture, Termination and Cancellation upon Termination of Service.  Notwithstanding any contrary provision of this Agreement or the Plan, in the event Participant ceases to continuously be (except for any absence for vacation, leave, etc. in accordance with the Company’s or its Subsidiaries’ 

  1

   

  	 

  |US-DOCS\127381020.1||	|  DATE \@ "MM-dd-yyyy" 12-30-2021|

  

   

  policies): (i) employed by the Company or any of its Subsidiaries, (ii) serving as a Non-Employee Director or (iii) providing services to the Company or any of its Subsidiaries as an advisor or consultant, then all RSUs that have not become vested on or prior to the date of such termination will thereupon be automatically forfeited by Participant without payment of any consideration therefor, and Participant, or Participant’s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.  No portion of the RSUs which has not become vested as of the date on which Participant ceases to continuously be (except for any absence for vacation, leave, etc. in accordance with the Company’s or its Subsidiaries’ policies): (i) employed by the Company or any of its Subsidiaries, (ii) serving as a Non-Employee Director or (iii) providing services to the Company or any of its Subsidiaries as an advisor or consultant shall thereafter become vested, except as may otherwise be provided by the Committee or as set forth in a written agreement between the Company (or any Subsidiary that is the employer of Participant) and Participant.

  II.6Issuance of Common Stock upon Vesting.  

  (a)As soon as administratively practicable following the vesting of any Restricted Share Units pursuant to Section 2.3 hereof, but in no event later than 30 days after such vesting date (for the avoidance of doubt, this deadline is intended to comply with the “short term deferral” exemption from Section 409A of the Code), the Company shall deliver to Participant (or any transferee permitted under Section 3.2 hereof) a number of Shares equal to the number of RSUs subject to this Restricted Share Unit Award that vest on the applicable vesting date.  Notwithstanding the foregoing, in the event the issuance of Shares is deferred pursuant to Sections 5.6 and 5.9 of the Plan, the Shares shall be issued pursuant to the preceding sentence as soon as administratively practicable after the Committee determines that Shares can again be issued in accordance with such Section.

  (b)As set forth in Section 5.5 of the Plan, the Company shall have the authority and the right to deduct or withhold, or to require Participant to remit to the Company, an amount sufficient to satisfy all applicable federal, state, local or other taxes (the “Tax-Related Items”) required by law to be withheld with respect to any taxable event arising in connection with the Restricted Share Units.  Such Tax-Related Items shall be satisfied by using a Sell to Cover pursuant to the Grant Notice.  The Company shall not be obligated to deliver any Shares to Participant or Participant’s legal representative unless and until Participant or Participant’s legal representative shall have paid or otherwise satisfied in full the amount of all Tax-Related Items applicable to the taxable income of Participant resulting from the grant or vesting of the Restricted Share Units or the issuance of Shares.  By accepting this award of RSUs, Participant has agreed to a Sell to Cover to satisfy any Tax-Related Items calculated at up to the maximum statutory tax rate, as determined by the Company, and Participant hereby acknowledges and agrees:

  (i)Participant hereby appoints the Agent as Participant’s agent and authorizes the Agent to (1) sell on the open market at the then prevailing market price(s), on Participant’s behalf, as soon as practicable on or after the date the Shares are issued upon vesting of the Restricted Share Units, that number (rounded up to the next whole number) of the Shares so issued necessary to generate proceeds to cover (x) any Tax-Related Items incurred with respect to such vesting or issuance based on up to the maximum statutory tax rates, as determined by the Company, and (y) all applicable fees and commissions due to, or required to be collected by, the Agent with respect thereto and (2) in the Company’s discretion, apply any remaining funds to Participant’s federal tax withholding or remit such remaining funds to Participant.

  (ii)Participant hereby authorizes the Company and the Agent to cooperate and communicate with one another to determine the number of Shares that must be sold pursuant to subsection (i) above.

  2

   

  	 

  |US-DOCS\127381020.1||	|  DATE \@ "MM-dd-yyyy" 12-30-2021|

  

   

  (iii)Participant understands that the Agent may effect sales as provided in subsection (i) above in one or more sales and that the average price for executions resulting from bunched orders will be assigned to Participant’s account.  In addition, Participant acknowledges that it may not be possible to sell Shares as provided in subsection (i) above due to (1) a legal or contractual restriction applicable to the Participant or the Agent, (2) a market disruption or (3) rules governing order execution priority on the national exchange where the Shares may be traded.  In the event of the Agent’s inability to sell Shares, Participant will continue to be responsible for the timely payment to the Company and/or its affiliates of all Tax-Related Items that are required by applicable laws and regulations to be withheld.

  (iv)Participant acknowledges that regardless of any other term or condition of this Section 2.6(b), the Agent will not be liable to Participant for (1) special, indirect, punitive, exemplary or consequential damages, or incidental losses or damages of any kind or (2) any failure to perform or for any delay in performance that results from a cause or circumstance that is beyond its reasonable control.

  (v)Participant hereby agrees to execute and deliver to the Agent any other agreements or documents as the Agent reasonably deems necessary or appropriate to carry out the purposes and intent of this Section 2.6(b).  The Agent is a third-party beneficiary of this Section 2.6(b).

  This Section 2.6(b) shall terminate not later than the date on which all tax withholding and obligations arising in connection with the vesting and issuance of the RSUs have been satisfied. 

  II.7Conditions to Delivery of Shares.  The Shares deliverable hereunder may be either previously authorized but unissued Shares, treasury Shares or issued Shares which have then been reacquired by the Company.  Such Shares shall be fully paid and nonassessable.  The Company shall not be required to issue Shares deliverable hereunder prior to fulfillment of the conditions set forth in Section 5.6 of the Plan.

  II.8Rights as Stockholder.  The holder of the RSUs shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of the RSUs and any Shares underlying the RSUs and deliverable hereunder unless and until such Shares shall have been issued by the Company and held of record by such holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).  No adjustment shall be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Sections 5.7 and 5.8 of the Plan.

  ARTICLE III.
OTHER PROVISIONS

  III.1Administration.  The Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules.  All actions taken and all interpretations and determinations made by the Committee in good faith shall be final and binding upon Participant, the Company and all other interested persons.  No member of the Committee or the Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the RSUs.  

  III.2Transferability.  The RSUs shall be subject to the restrictions on transferability set forth in Section 5.4 of the Plan.

  3

   

  	 

  |US-DOCS\127381020.1||	|  DATE \@ "MM-dd-yyyy" 12-30-2021|

  

   

  III.3Tax Consultation.  Participant understands that Participant may suffer adverse tax consequences in connection with the RSUs granted pursuant to this Agreement (and the Shares issuable with respect thereto).  Participant represents that Participant has consulted with any tax consultants Participant deems advisable in connection with the RSUs and the issuance of Shares with respect thereto and that Participant is not relying on the Company for any tax advice.

  III.4Binding Agreement.  Subject to the limitation on the transferability of the RSUs contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.

  III.5Adjustments Upon Specified Events.  The Committee may accelerate the vesting of the RSUs in such circumstances as it, in its sole discretion, may determine.  Participant acknowledges that the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and Sections 5.7 and 5.8 of the Plan.

  III.6Notices.  Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company at the Company’s principal office, and any notice to be given to Participant shall be addressed to Participant at Participant’s last address reflected on the Company’s records.  By a notice given pursuant to this Section 3.6, either party may hereafter designate a different address for notices to be given to that party. Any notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service (or similar non-U.S. entity).

  III.7Participant’s Representations.  If the Shares issuable hereunder have not been registered under the Securities Act or any applicable state laws on an effective registration statement at the time of such issuance, Participant shall, if required by the Company, concurrently with such issuance, make such written representations as are deemed necessary or appropriate by the Company or its counsel.

  III.8Titles.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.

  III.9Governing Law.  The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws.  By entering into this Agreement, Participant irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of Delaware and of the United States of America, in each case located in the State of Delaware, for any action arising out of or relating to this Agreement and the Plan (and agrees not to commence any litigation relating thereto except in such courts), and further agrees that service of any process, summons, notice or document by U.S. registered mail to the address contained in the records of the Company shall be effective service of process for any litigation brought against it in any such court.  By entering into this Agreement, Participant irrevocably and unconditionally waives any objection to the laying of venue of any litigation arising out of the Plan or this Agreement in the courts of the State of Delaware or the United States of America, in each case located in the State of Delaware, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such litigation brought in any such court has been brought in an inconvenient forum.  By entering into this Agreement, Participant irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any and all rights to trial by jury in connection with any litigation arising out of or relating to the Plan or this Agreement.

  III.10Conformity to Securities Laws.  Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the 

  4

   

  	 

  |US-DOCS\127381020.1||	|  DATE \@ "MM-dd-yyyy" 12-30-2021|

  

   

  Exchange Act and any other applicable law.  Notwithstanding anything herein to the contrary, the Plan shall be administered, and the RSUs are granted, only in such a manner as to conform to applicable law.  To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such applicable law.

  III.11Amendment, Suspension and Termination.  To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board; provided, however, that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the RSUs in any material way without the prior written consent of Participant.    

  III.12Successors and Assigns.  The Company may assign any of its rights and delegate any of its obligations under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth in Section 3.2 hereof, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.

  III.13Limitations Applicable to Section 16 Persons.  Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, then the Plan, the RSUs and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule.  To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.

  III.14Not a Contract of Service Relationship.  Nothing in this Agreement or in the Plan shall confer upon Participant any right to commence or continue to serve as an employee or other service provider or shall interfere with or restrict in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise by applicable law or in a written agreement between the Company or a Subsidiary (as applicable) and Participant.

  III.15Entire Agreement.  The Plan, the Grant Notice and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof, provided that the RSUs shall be subject to any accelerated vesting provisions in any written agreement between Participant and the Company (or any Subsidiary who is the employer of Participant) or a Company plan pursuant to which Participant is eligible to participate, in each case, in accordance with the terms therein. 

  III.16Section 409A.  This Restricted Share Unit Award is not intended to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, “Section 409A”).  However, notwithstanding any other provision of the Plan, the Grant Notice or this Agreement, if at any time the Committee determines that this Restricted Share Unit Award (or any portion thereof) may be subject to Section 409A, the Committee shall have the right in its sole discretion (without any obligation to do so or to indemnify Participant or any other person for failure to do so) to adopt such amendments to the Plan, the Grant Notice or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Committee determines are necessary or appropriate for this Restricted Share Unit Award either to be exempt from the application of Section 409A or to comply with the requirements of Section 409A. 

  5

   

  	 

  |US-DOCS\127381020.1||	|  DATE \@ "MM-dd-yyyy" 12-30-2021|

  

   

  III.17Limitation on Participant’s Rights.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Participant shall have only the rights of a general unsecured creditor of the Company and its Subsidiaries with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to RSUs, as and when payable hereunder. 

  III.18Rules Particular To Specific Countries.  

  (a)Generally.  Participant shall, if required by the Committee, enter into an election with the Company or a Subsidiary (in a form approved by the Company) under which any liability to the Company’s (or a Subsidiary’s) Tax-Related Items, including, but not limited to, National Insurance Contributions (“NICs”) and the Fringe Benefit Tax, is transferred to and met by Participant.  

  (b)Tax Indemnity.  Participant shall indemnify and keep indemnified the Company and any of its subsidiaries from and against any Tax-Related Items.

  III.19Special Country Provisions for RSUs Granted to Participants.  The RSUs shall be subject to additional country provisions as set forth in Section 5.14 of the Plan, if any, for Participant’s country of residence.  If Participant relocates to one of the countries outside of the US during the life of the RSUs, special provisions for such country may apply to Participant, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.  The Company reserves the right to impose other requirements on the RSUs and the Shares issuable upon settlement of the RSUs, to the extent the Company determines it is necessary or advisable in order to comply with local laws or facilitate the administration of the Plan, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.

  *     *     *     *     *

  6

   

  	 

  |US-DOCS\127381020.1||	|  DATE \@ "MM-dd-yyyy" 12-30-2021|EX-10.20

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

  Exhibit 10.20

  AMENDMENT NO. 2 TO THE

  COLLABORATION AND LICENSE AGREEMENT

   

  This Amendment No. 2 to the Collaboration Agreement (this “Amendment”) is effective as of the 27th day of October, 2021 (the “Amendment Effective Date”) by and between Amgen Inc., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”) and CytomX Therapeutics, Inc., a Delaware corporation having an address at 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (“CytomX”). Amgen and CytomX are each hereafter referred to individually as a “Party” and together as the “Parties”.

   

  WHEREAS, Amgen and CytomX entered into that certain Collaboration and License Agreement, dated as of September 29, 2017, as amended (the “Agreement”); and

   

  WHEREAS, Amgen and CytomX wish to amend certain additional terms of the Agreement as further provided herein; and

   

  NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the Parties agree to amend the Agreement as follows. Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.

   

  PART 1 - AMENDMENTS TO CERTAIN TERMS

   

   

  1.Amendment to Section 2.1.5(c)(i).	From and after the Amendment Effective Date, Section 2.1.5(c)(i) is hereby deleted and replaced in its entirety as follows:

   

  “(i) [***]shall decide matters with respect to [***] through the [***], other than [***], which shall be decided by [***]; provided that, notwithstanding     anything to the contrary herein:

   

  (A)no such exception for [***] right to decide [***]shall apply, and instead [***]shall have the right to decide all matters, with respect to the decision to [***], without  needing first to escalate such matters to the Executive Officers for resolution if the JSC does not reach consensus after its discussion of such matters, and

   

  (B)following expiration of the [***] without [***]occurring prior thereto, [***]shall have the right

   

   

   

  1

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

   

   

   

  to decide any [***]with respect to the conduct of the [***] to be conducted for [***], provided that if such decision would result in [***]incurring costs beyond [***] of the costs set forth in the budget for such study set forth in the [***] approved by the JSC on [***], then [***] shall only have the right to decide such matter if [***]agrees to bear the excess costs; and”

   

  2.Amendment to Section 4.4.1. Effective as of September 29, 2021, Section 4.4.1 is hereby deleted and replaced in its entirety as follows:

   

  “4.4.1 Amgen shall have the right to elect to select (a) one (1) additional Target (the “First Additional Amgen Target”) by nominating such additional Target at any time prior to [***] (the “First Additional Amgen Target Selection Date”) for inclusion under this Agreement, subject to Section 4.4.2 and

  (b) a second (2nd) additional Target (the “Second Additional Amgen Target” and, together with the First Additional Amgen Target, the “Additional Amgen Targets”) by nominating such additional Target at any time prior to [***] (the “Second Additional Amgen Target Selection Date” and, together with    the First Additional Amgen Target Selection Date, the “Selection Dates”) for inclusion under this Agreement, subject to Section 4.4.2 (collectively, the “Amgen Expansion Option”).”

   

  3.Amendment to  Section 6.1.3 (EGFR Products).	From and after the Amendment Effective Date, Section 6.1.3 (EGFR Products) is hereby amended as follows:

   

  Section 6.1.3 is hereby deleted and replaced in its entirety as follows:

   

  “6.1.3 EGFR Products. Following the Effective Date and at all times during the Term (except with respect to Preclinical Development and clinical activities conducted by each Party pursuant to the Preclinical Development Plan and EGFR Initial Development Plan, and except as set forth in clauses (a) and (b) below), Amgen shall be responsible for, and shall bear all costs associated with, the development, manufacture and commercialization of EGFR Products, including development, distribution, marketing and sales activities. For clarity, after completion of the Preclinical Development Plan and [***], and notwithstanding any other activities conducted by CytomX pursuant to the EGFR Initial Development Plan, if [***], Amgen shall continue to have the right to conduct preclinical and clinical development with respect to all EGFR Products. Subject to the terms of this Agreement, [***]. After completion of CytomX’s activities as set forth in the Preclinical Development Plan and EGFR Initial Development Plan and [***] , CytomX will promptly transfer to Amgen all CytomX Licensed Know-How as is reasonably necessary or useful for Amgen to develop and seek Marketing Approval for the EGFR Products, including all materials for supporting regulatory filings consistent with Amgen’s obligations under Article 5.  Notwithstanding the foregoing:”

   

   

   

  2

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

  Section 6.1.3(a) is hereby deleted and replaced in its entirety as follows:

   

  “(a) CytomX shall be responsible for conducting any EGFR Dose Escalation Study and any EGFR Cohort Expansion Study pursuant to the EGFR Initial Development Plan, with costs borne by [***]. With respect to the first EGFR Dose Escalation Study included in the EGFR Initial Development Plan approved by the [***]:

   

  (i)CytomX shall provide the JSC updates on such EGFR Dose Escalation Study once per Calendar Quarter and, notwithstanding Section 3.3, provide data generated under such EGFR Dose Escalation Study only upon the completion thereof as part of the Data Package or upon Amgen’s written request.

   

  (ii)No later than [***]days after the date that [***] decides to progress to the EGFR Cohort Expansion Study for CX-904 with patient data that includes [***], CytomX shall deliver to Amgen the data package containing the information set forth in Appendix A (“Data Package”). Amgen shall have [***]days after receipt of the Data Package (the “Review Period”) to review the Data Package and, if during the Review Period Amgen believes in good faith that any information required to be included in the Data Package is missing, then Amgen shall have the right to request in writing that CytomX update the Data Package to include any such missing information in the possession of CytomX and CytomX shall deliver a revised Data Package within [***]days after receipt of such request. The Review Period shall be extended by the number of days between the date of Amgen’s request for such information and the date of receipt of the revised Data Package. [***]

   

  (iii)On or prior to the expiration of the Review Period, Amgen shall [***]. If Amgen does not provide such notice on or prior to the expiration of the Review Period, then Amgen shall [***]. For clarity, if [***], Amgen shall [***].”

   

  4.Amendment to Section 7.3.2. From and after the Amendment Effective Date, Section

  7.3.2 (Certain CytomX EGFR Costs) is hereby deleted and replaced in its entirety as follows:

   

  “7.3.2 Certain CytomX EGFR Costs. CytomX shall be responsible for [***]  with respect to the first EGFR Dose Escalation Study and the first EGFR Cohort Expansion Study; provided, however, that Amgen  shall reasonably assist CytomX upon CytomX’s request [***], which shall include reviewing [***].”

   

  5.Amendment to Section 7.4.3 (EGFR Products). From and after the Amendment Effective Date, the “Development and Regulatory Milestone Events” table in Section 7.4.3 (EGFR Products) is hereby deleted and replaced in its entirety as follows:

   

   

   

  3

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

  				
	 
 
Milestone Event
	Milestone Payment

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]

   

  6.Amendment to Section 7.4.4. From and after the Amendment Effective Date, the following sentence in Section 7.4.4, “For EGFR Products, the maximum amount payable

   

   

   

  4

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

   

   

   

  under this Section 7.4 is Four Hundred Fifty-Five Million Dollars ($455,000,000).” is hereby deleted and replaced in its entirety as follows:

   

  “For EGFR Products, the maximum amount payable under this Section 7.4 is Four Hundred Sixty Million Dollars ($460,000,000).”

   

  7.Amendment to Section 8.2.3 (Collaboration Patents). From and after the Amendment Effective Date, the first, second and third sentences in Section 8.2.3 (Collaboration Patents) are hereby deleted and replaced in their entirety as follows:

   

  “CytomX will have the first right, [***], but not the obligation, to assume responsibility for preparing, filing, prosecuting (including, but not limited to provisional, reissue, reexamination, continuing, divisional, continuation, continuation-in-part, and substitute applications and any foreign counterparts thereof), and maintaining [***] (a) [***] (i) [***] and (ii) [***], (b) [***], (c) [***] or

  (d) subject to the rest of this Section 8.2.3, [***], and in each case, conducting any interferences and oppositions or similar proceedings relating to such Patent Rights. [***]. Amgen will have the first right, but not the obligation, [***], for preparing, filing, prosecuting (including, but not limited to provisional, reissue, reexamination, continuing, divisional, continuation, continuation-in-part, and substitute applications and any foreign counterparts thereof), and    maintaining [***], and in each case, conducting any interferences and oppositions or similar proceedings relating to such Patent Rights. [***]. For clarity, following  [***], if Amgen has not [***], and [***] has not occurred, prior to [***], Amgen shall [***].”

   

   

   

  5

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

   

   

   

  8.Amendment to Section 12.2.2 (Review). From and after the Amendment Effective Date, the last sentence of Section 12.2.2 (Review) is hereby deleted and replaced in its entirety as follows:

   

  “Either Party, subject to the other Party’s written consent, not to be unreasonably withheld, delayed or conditioned, may make disclosures relating to the development or commercialization of an EGFR Product, including the results of research and any clinical trial conducted by the Parties or any health or safety matter related to an EGFR Product, except that [***], [***], provided that at least [***] days in advance of any such disclosure, [***]shall provide [***]with a copy of and timing of such disclosure and [***]shall consider in good faith any comments on such disclosure provided by [***]; provided, however, that from and after the EGFR Cohort Expansion Study Completion Date, [***]shall be entitled to direct the disclosure strategy with respect to EGFR Products and may make any such disclosure prior to disclosure by [***].”

   

  9.Amendment to Section 12.3 (Publication). From and after the Amendment Effective Date, the first and second sentences of Section 12.3 (Publication) are hereby deleted and replaced in their entirety as follows:

   

  “CytomX will have the sole right to publish and make scientific presentations with respect to CytomX Platform Technology, CytomX Products and [***], any results of the first EGFR Dose Escalation Study, and to issue press releases (except with respect to the terms of this Agreement, which is governed by Section 12.2) or  make other public disclosures regarding any such CytomX Platform Technology, CytomX Products and [***], any results of the first EGFR Dose  Escalation Study, and Amgen will not do so without CytomX’s prior written consent, except as required by Law; provided, however, that any publication or presentation to be made by CytomX that names Amgen will require the prior written consent of Amgen. Amgen will have the sole right to publish and make scientific presentations with respect to Amgen Products or EGFR Products other than the results of the first EGFR Dose Escalation Study prior to [***], and to issue press releases (except with respect to the terms of this Agreement, which is governed by Section 12.2) or make other public disclosures regarding any such Amgen Products or such EGFR Products, and CytomX will not do so without Amgen’s prior written consent, except as required by Law or in connection with any research or clinical trial conducted by CytomX prior to the EGFR Cohort Expansion Study Completion Date; provided, however, that any publication or presentation to be made by Amgen that names CytomX will require the prior written consent of CytomX and vice versa.”

   

  10.Amendment to Section 13.3.2 (Discretionary Termination). From and after the Amendment Effective Date, the following sentence is hereby added at the end of Section

  13.3.2 (Discretionary Termination):

   

   

   

  6

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

   

   

   

  “Notwithstanding the foregoing, if Amgen provides notice of termination of this Agreement with respect to the EGFR Target and EGFR Products and the rights and obligations thereunder during [***], then (a) such termination shall be effective [***]and (b) notwithstanding Section 13.6 or achievement of the Initiation of first EGFR Cohort Expansion Study Milestone Event, Amgen shall not be obligated to [***].”

   

  11.Amendment to Section 13.5 (Effect of Termination With Respect to EGFR Target and EGFR Products). From and after the Amendment Effective Date, Section 13.5 (Effect of Termination With Respect to EGFR Target and EGFR Products) is hereby amended as follows:

  The third sentence of Section 13.5(e) is hereby deleted and replaced in its entirety as follows:

  “To the extent the foregoing license is [***], [***] shall [***] to [***]on [***]at [***]: (i) if [***], (ii) if [***] or (iii) if [***].”

   

  The following Section 13.5(i) is hereby added to Section 13.5:

  “(i) If [***], or [***], at [***] request, (A) [***]shall assign (or, if applicable, cause   its Affiliate to assign) to [***]all of [***] (and such Affiliates’) right, title and interest in and to any [***], at [***] expense, and (B) with respect to all other [***] or its Affiliates that [***], if [***], then (1) [***]shall provide [***]with reasonable notice of such decision (which notice shall in any event be given no later than [***] days prior to the next deadline for any action that may be taken with respect to such [***] with the U.S. Patent & Trademark Office or any foreign patent office), (2) [***]shall have the right to elect, by written notice to [***], to [***], and (3) [***]shall, at [***] reasonable request and expense, assist  and cooperate in [***].”

   

  PART 2 – REFERENCE TO AND EFFECT ON THE AGREEMENT

   

  1.1Reference to Agreement. Upon and after the effectiveness of this Amendment, each reference in the Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Agreement shall mean and be a reference to the Agreement as modified and amended hereby.

   

  1.2Effectiveness of Amendment. Upon execution and delivery of this Amendment by the Parties, the amendments set forth above shall be effective as of the Amendment Effective Date. Except as specifically amended above, the Agreement is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed and shall constitute the legal, valid, binding and enforceable obligations of the Parties.

   

  PART 3 – MISCELLANEOUS

  1.1Choice of Law; Jurisdiction. This Amendment and its effect are subject to and shall be 

   

   

  7

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

  construed and enforced in accordance with the law of the State of New York, without regard to its conflicts of laws, except as to any issue which depends upon the validity, scope or enforceability of any Amgen Patent, CytomX Patent or Collaboration Patent, which issue shall be determined in accordance with the laws of the country in which such patent was issued. Each of the Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of New York located in the City of New York for any matter arising out of or relating to this Amendment and the transactions contemplated hereby, and agrees not to commence any litigation relating thereto except in such courts. Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Amendment or the transactions contemplated hereby in the courts of the State of New York located in the City of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum. The Parties agree that a final judgment in any such matter shall be conclusive and may be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law. Any proceeding brought by either Party under this Amendment shall be exclusively conducted in the English language.

  1.2Headings. Article and Section headings used herein are for convenient reference only, and are not a part of this Amendment.

  1.3Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. This Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.

  [Signature page follows]

   

   

   

  8

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

   

   

   

  IN WITNESS THEREOF, duly authorized representatives of the Parties hereto have executed this Amendment No. 2 as of the date first set forth above.

   

   

  AMGEN INC.

   

   

   

   

   

   

   

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

  By:

  

   

   

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

   

   

   

   

  

   

  DocuSign Envelope ID: BC0B85A8-4C4E-49BF-9DC2-0D8965BBCF25

   

   

  Name:	[***]

   

  Title:	[***]

   

   

   

   

   

  CYTOMX THERAPEUTICS, INC.

   

   

  By:

  Name:	[***]

   

  Title:	[***]

   

   

   

   

  

   

   

   

   

  Appendix A

   

                                                                       [***]

   

   

  Appendix A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]